Raising New Hope for Controlling Seizures in Focal Cortical Dysplasia with Gene Therapy  

作　　者：Yuanzhi Yang Yang Zheng Zhong Chen Cenglin Xu 

机构地区：[1]Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province,School of Pharmaceutical Sciences,Xinhua Hospital of Zhejiang Province,The Second Affiliated Hospital of Zhejiang Chinese Medical University,Zhejiang Chinese Medical University,Hangzhou,310053,China

出　　处：《Neuroscience Bulletin》2024年第7期1028-1030,共3页神经科学通报（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(82330116 and 82374064);the Natural Science Foundation of Zhejiang Province(LD22H310003).

摘　　要：Focal cortical dysplasia(FCD)is characterized by abnormal cortical development and pharmacoresistant epilepsy,often accompanied by cognitive and behavioral malfunctions[1].According to the International League against Epilepsy(ILAE)classification proposed by Najm,Imad et al.in 2022,FCD can be further divided into isolated forms(FCD type Ⅰ and Ⅱ)and another type associated with a principal lesion(FCD type Ⅲ)[2].

关 键 词：EPILEPSY al. THERAPY 

分 类 号：R742.1[医药卫生—神经病学与精神病学]